Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$167,575 | -$153,162 | $109,195 | -$67,485 |
| Dep. & Amort. | $306 | $310 | $93 | $53 |
| Deferred Tax | $0 | $0 | $0 | $3,098 |
| Stock-Based Comp. | $37,824 | $30,438 | $27,957 | $24,375 |
| Change in WC | -$389 | -$339 | $11,176 | -$3,541 |
| Other Non-Cash | -$15,469 | -$11,522 | -$275,085 | $67 |
| Operating Cash Flow | -$145,303 | -$134,275 | -$126,664 | -$43,433 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$208 | -$1,133 | -$589 |
| Net Acquisitions | $0 | -$36 | $275,000 | $923 |
| Inv. Purchases | -$721,131 | -$373,383 | -$377,916 | -$525,813 |
| Inv. Sales/Matur. | $584,817 | $409,397 | $352,933 | $192,038 |
| Other Inv. Act. | $0 | $36 | $91 | -$334 |
| Investing Cash Flow | -$136,314 | $35,806 | $248,975 | -$333,775 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $1,825 | -$2,200 | $0 |
| Stock Issued | $262,652 | $38,388 | $8,395 | $267,268 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $3,536 | $538 | -$32,128 | $1,516 |
| Financing Cash Flow | $266,188 | $40,751 | -$25,933 | $268,784 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$15,429 | -$57,718 | $96,378 | -$108,424 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $98,434 | $156,152 | $59,774 | $168,198 |
| End Cash | $83,005 | $98,434 | $156,152 | $59,774 |
| Free Cash Flow | -$145,303 | -$134,483 | -$127,797 | -$44,022 |